Legend Biotech Corporation

Equities

LEGN

US52490G1022

Market Closed - Nasdaq Other stock markets 21:00:00 12/12/2025 GMT			5-day change	1st Jan Change
22.32 ^USD	-3.00%		-20.65%	-31.41%

12-10	Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says	MT
12-08	UBS Adjusts Legend Biotech Price Target to $48 From $54, Maintains Buy Rating	MT

Transcript : Legend Biotech Corporation, Q2 2024 Earnings Call, Aug 09, 2024

Published on 08/09/2024 at 01:00 pm BST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech's Second Quarter 2024 Earnings Conference Call. [Operator Instructions]

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Legend Biotech Corporation

12-10	Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says	MT
12-08	UBS Adjusts Legend Biotech Price Target to $48 From $54, Maintains Buy Rating	MT
12-06	Legend Biotech highlights new Carvykti® data in multiple myeloma and first-in-human results from novel CAR-T platform in non-Hodgkin lymphoma at ASH 2025	RE
11-13	Legend Biotech Corporation Celebrates Official Opening of New Cell Therapy Research and Development Facility in Philadelphia	CI
11-13	RBC Trims Price Target on Legend Biotech to $74 From $75, Keeps Outperform Rating	MT
11-13	Truist Lowers Price Target on Legend Biotech to $70 From $71, Keeps Buy Rating	MT
11-12	Legend Biotech Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-12	Legend Biotech Corporation, Q3 2025 Earnings Call, Nov 12, 2025
11-12	Legend Biotech Q3 Adjusted Loss Narrows, Revenue Rises	MT
11-12	Legend Biotech Q3 revenue slightly misses estimates	RE
11-12	Earnings Flash (LEGN) Legend Biotech Corporation Reports Q3 Revenue $272.3M, vs. FactSet Est of $274.4M	MT
11-12	Earnings Flash (LEGN) Legend Biotech Corporation Posts Q3 Adjusted Loss $0.05 per Share	MT
10-15	GenScript Associate Books $524 Million in Q3 CARVYKTI Sales	MT
10-14	Cabaletta Bio, Inc. Announces the Appointment of Steve Gavel as Chief Commercial Officer, Effective from October 14, 2025	CI
10-14	Legend Biotech Corporation Announces U.S. Fda Approves Label Updates for Carvykti® Car-T Cell Therapy to Include Overall Survival Data	CI
10-13	The Presidential Whiplash Index
10-13	US FDA adds label warning to J&J's and Legend Biotech's cancer therapy	RE
10-08	RBC Trims Price Target on Legend Biotech to $75 From $77, Keeps Outperform Rating	MT
10-07	Legend Biotech Signs New Supply Deal With Janssen for Ciltacabtagene Autoleucel	MT
10-07	Legend Biotech USA Inc. Enters into Component and Product Supply Agreement with Janssen Pharmaceuticals, Inc	CI
09-10	Legend Biotech Corporation Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 04:05 PM
09-05	Sector Update: Health Care Stocks Rise Friday Afternoon	MT
09-05	Sector Update: Health Care	MT
09-05	Legend Biotech Said to Consider Second Listing Outside US	MT
09-05	Legend Biotech Said to Consider Second Listing Outside US, Bloomberg Reports	MT